June 2026

Dr. Chetan Kalal has been invited as Faculty to the LTSICON 2026 Midterm Conference in Pune, where he will lead a Case-Based Panel Discussion on Viral and Invasive Fungal Infection: Cause and Effect Relationship with Graft Dysfunction — one of the most complex and clinically consequential topics in post-liver transplant medicine. LTSICON (Liver Transplant Society of India Conference) is India’s premier liver transplantation conference, convening the country’s leading transplant surgeons, hepatologists, intensivists, and allied specialists. Invitation as faculty to a case-based panel discussion represents the highest tier of participation — it is a recognition of subspecialty depth, not just attendance. About LTSICON 2026 — Midterm, Pune The Liver Transplant Society of India (LTSI) organises both an annual conference and a midterm conference, with rotating national venues. The midterm format typically focuses on intensive clinical learning — case-based discussions, controversial topics, and subspecialty deep-dives that the larger annual meeting cannot accommodate in the same depth. The case-based panel discussion format places real, de-identified transplant cases before a panel of experts who debate diagnosis, management decisions, and outcomes in real time — the most intellectually demanding and educationally effective format in post-graduate medical education. Dr. Kalal’s invitation to faculty this session reflects his standing as one of India’s authoritative voices on post-transplant infectious complications and graft dysfunction — a domain that sits at the intersection of transplant hepatology, infectious disease, and critical care. The clinical topic: Viral and Invasive Fungal Infection — Cause and Effect with Graft Dysfunction Post-liver transplant infections are the leading cause of morbidity and mortality in the first year after transplantation. The relationship between infection and graft dysfunction is bidirectional and frequently misunderstood in non-specialist settings: infections cause graft dysfunction, and graft dysfunction predisposes to infections. Untangling this relationship determines whether a deteriorating graft is rejected, infected, or both — and the treatment is fundamentally different for each. Viral infections and graft dysfunction — the CMV problem Cytomegalovirus (CMV) is the most clinically significant viral pathogen after liver transplantation. It causes two distinct problems: Direct CMV disease: CMV hepatitis (the graft itself is the target — rising LFTs, histology showing cytomegalic inclusions), CMV colitis, CMV pneumonitis. In the graft, CMV hepatitis causes a pattern of liver dysfunction that mimics rejection on biochemistry — the distinction requires liver biopsy with immunohistochemistry. Indirect CMV effects: CMV is immunomodulatory — it broadly suppresses immune function, increasing susceptibility to other opportunistic infections (bacterial, fungal, other viral). CMV-seropositive recipients receiving organs from CMV-seropositive donors (D+/R+) are at highest risk of clinically significant disease. Standard prophylaxis: valganciclovir for 3–6 months post-transplant in high-risk patients. Breakthrough CMV despite prophylaxis, or CMV disease in a patient on prophylaxis, requires intravenous ganciclovir and resistance testing. Ganciclovir-resistant CMV (UL97 and UL54 mutations) is an emerging problem requiring foscarnet — a nephrotoxic agent — creating a management dilemma in patients already receiving calcineurin inhibitors. Epstein-Barr Virus (EBV) and PTLD EBV causes post-transplant lymphoproliferative disorder (PTLD) — a spectrum from infectious mononucleosis-like illness to aggressive B-cell lymphoma. PTLD is the most feared late viral complication of immunosuppression. EBV viral load monitoring (quantitative PCR) is mandatory in EBV-seronegative recipients (R-) receiving organs from EBV-positive donors (D+) — the highest-risk combination, common in paediatric transplantation. Graft dysfunction in PTLD can occur via hepatic PTLD (infiltration of the liver graft by lymphoproliferative cells) or via systemic disease with secondary hepatic involvement. The key clinical challenge is distinguishing PTLD from rejection on liver biopsy — both can cause portal inflammation and bile duct injury. Other viral pathogens Hepatitis B recurrence: HBV recurrence in the graft after liver transplantation for HBV-related cirrhosis — prevented with lifelong antiviral therapy (tenofovir or entecavir) plus hepatitis B immunoglobulin (HBIG) in the perioperative period. Fibrosing cholestatic hepatitis B (FCH-B) is a devastating form of graft HBV recurrence with rapid progression to graft failure. HCV recurrence: Now effectively treated with direct-acting antivirals (DAAs) post-transplant; fibrosing cholestatic hepatitis C (FCH-C) is rare with current prophylaxis and early treatment. Adenovirus, HHV-6, parvovirus B19: Less common but clinically significant in immunosuppressed recipients; may cause hepatitis, bone marrow suppression, or encephalitis depending on the pathogen. Invasive fungal infections — the underestimated threat Invasive fungal infections (IFIs) after liver transplantation carry mortality rates of 50–90% for invasive aspergillosis and 30–50% for invasive candidiasis, even with optimal antifungal therapy. They occur predominantly in the first 30–90 days post-transplant, when immunosuppression is most intense and surgical trauma to the biliary tree and vasculature creates entry points. Invasive candidiasis (Candida albicans, Candida glabrata, Candida krusei) is the most common IFI in liver transplant recipients. Risk factors: prolonged surgery, Roux-en-Y biliary reconstruction, renal replacement therapy, re-transplantation, high intraoperative transfusion requirements. Treatment: echinocandins (caspofungin, micafungin) first-line; azoles for step-down. Candida glabrata and krusei have intrinsic azole resistance — species identification and sensitivity testing are essential. Invasive aspergillosis (Aspergillus fumigatus predominantly) — the most lethal IFI post-transplant. Pulmonary aspergillosis presenting as cavitating lung lesions in a recipient on high-dose steroids (e.g., post-rejection treatment) is classic. CT chest showing “halo sign” — a nodule surrounded by ground-glass opacity — is the hallmark finding. Treatment: voriconazole first-line; isavuconazole as alternative. Critical interaction: voriconazole is a potent CYP3A4 inhibitor that dramatically increases tacrolimus levels — dose reduction of tacrolimus by 50–75% required immediately on initiation, with twice-weekly tacrolimus monitoring until stable. Mucormycosis — rare but increasingly reported post-transplant, particularly in diabetic recipients or those receiving high steroid doses. Angio-invasive, rapidly fatal without surgical debridement plus liposomal amphotericin B. COVID-19-associated mucormycosis (CAM) was disproportionately reported in India in 2021 in immunosuppressed patients, including transplant recipients. Pneumocystis jirovecii pneumonia (PJP) — prevented with trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis for the first 6–12 months post-transplant. Breakthrough PJP in a recipient on prophylaxis suggests compliance failure, drug interaction, or unusually intense immunosuppression. The cause-and-effect relationship with graft dysfunction This is the crux of Dr. Kalal’s panel discussion — and the area where clinical errors most commonly occur: Infection causing graft dysfunction: CMV hepatitis raises LFTs and bilirubin, mimicking rejection. Fungal cholangitis (Candida in the biliary tree post-Roux-en-Y reconstruction) causes

Finding the right hepatologist in Mumbai or India is not straightforward. The category is loosely used — “liver specialist” can mean a gastroenterologist with a liver interest, a general physician managing hepatitis, or a fully trained DM Hepatologist with dedicated subspecialty experience in transplantation, ACLF, and complex liver disease. The difference matters significantly when the diagnosis is serious. This article clarifies what to look for, who qualifies as India’s best hepatologist, and how to access the right expertise whether you are in Mumbai, another Indian city, or abroad. What makes someone India’s best hepatologist? The term is used widely and verified rarely. The meaningful criteria are: Qualification: DM (Hepatology) — India’s highest subspecialty degree in liver disease, awarded after a three-year dedicated training program beyond MD. Distinct from DM Gastroenterology and from MD/DNB with a liver interest. Transplant experience: Direct involvement in liver transplant evaluation, MELD-based listing, LDLT (living donor liver transplant) candidacy assessment, and post-transplant aftercare — not merely referral to a surgical team. Critical care exposure: Direct management of ACLF, acute liver failure, variceal bleeding, SBP, HRS, and hepatic encephalopathy in an inpatient and ICU setting. Research and publication: Peer-reviewed output in hepatology — not padded citation counts but original clinical research, preferably indexed in PubMed with multi-centre or guideline-level impact. International recognition: Membership of EASL, AASLD, APASL, and recognition via fellowship, award, or faculty invitation from these bodies. Dr. Chetan Kalal holds DM (Hepatology), MD (Medicine), and MRCP (UK). He is the first DM-qualified Hepatologist in Maharashtra, Associate Director of Hepatology & Transplant Medicine at Gleneagles Hospital Mumbai, and has 26+ PubMed-indexed publications. He has been recognised with the AASLD Foundation Award and serves as faculty at national and international hepatology conferences. Best hepatologist in Mumbai — what the title should mean Mumbai has multiple hospitals offering hepatology services. The distinction between a good hepatologist and the best hepatologist in Mumbai comes down to: Subspecialty DM training (not just a gastroenterologist who sees liver cases) Active liver transplant programme involvement — including LDLT, which is the dominant modality in India Management of high-acuity presentations: ACLF grade 3, acute liver failure, refractory ascites, multi-organ dysfunction Availability for second opinions, structured virtual consultations, and NRI care coordination Dr. Chetan Kalal practises at Gleneagles Hospital Mumbai as Associate Director, with additional consultant appointments at Breach Candy Hospital, Khar Hinduja Hospital, and Saifee Hospital — covering South Mumbai, Khar, and the broader city geography. Best liver transplant specialist in Mumbai Liver transplantation in India is primarily living donor liver transplantation (LDLT) — a technically demanding modality where a lobe of the liver from a healthy living donor is transplanted into the recipient. The hepatologist’s role in a transplant programme is distinct from the surgeon’s: Pre-transplant: Establishing transplant candidacy, MELD scoring, listing decisions, managing the patient while awaiting transplant, bridging therapies for HCC Donor evaluation: Medical assessment of the living donor — ruling out contraindications, ensuring donor safety Post-transplant: Immunosuppression management (tacrolimus, mycophenolate, steroids), rejection surveillance, CMV/EBV monitoring, long-term graft health, managing metabolic complications after transplant A liver transplant specialist in Mumbai who is also a DM Hepatologist provides integrated pre- and post-transplant medical care — the physician-side of the transplant, not just the surgical procedure. Dr. Chetan Kalal provides complete liver transplant physician care: pre-transplant candidacy evaluation, MELD-based listing, LDLT donor assessment coordination, and comprehensive post-transplant medical aftercare including immunosuppression, graft monitoring, and long-term follow-up. He practises at Gleneagles Hospital Mumbai. Best hepatologist in India — national perspective India has a small number of DM-qualified hepatologists distributed across major cities — primarily Mumbai, Delhi, Chennai, Hyderabad, Kolkata, and Ahmedabad. The concentration is highest in tertiary liver centres attached to major hospitals or medical institutes (ILBS Delhi, PGIMER Chandigarh, CMC Vellore, AIIMS, and select private hospitals). For patients from any Indian city seeking subspecialty hepatology review: In person — Mumbai: Gleneagles Hospital Mumbai is accessible from all major Indian cities via direct flight. South Mumbai location (Breach Candy) is also available. Virtual consultation: A full structured hepatology consultation — review of all records, video call, written clinical summary — is available from any location in India without travel to Mumbai. Conditions for which all-India patients most commonly seek Dr. Kalal’s opinion: ACLF (second opinion on grade, management, and transplant candidacy), autoimmune hepatitis (diagnosis confirmation, treatment adequacy), Wilson’s disease, HCC staging, post-transplant complications, and decompensated cirrhosis with unclear aetiology. Best liver transplant specialist in India India performs among the highest volumes of LDLT globally, concentrated in Mumbai, Delhi, and Chennai. The best liver transplant specialist in India is one who combines: DM Hepatology training with direct transplant programme integration High-volume LDLT experience — both evaluation and post-transplant management Familiarity with MELD 3.0, current EASL and APASL transplant criteria, and ACLF-to-transplant pathways Ability to manage complex post-transplant scenarios: calcineurin inhibitor toxicity, de novo autoimmune hepatitis post-transplant, recurrent HCV/HBV in graft, metabolic syndrome after transplant For NRI patients who received a liver transplant in India and subsequently relocated abroad — to the UK, USA, UAE, Singapore, or Australia — ongoing post-transplant hepatology follow-up with Dr. Kalal is available via structured virtual consultation, coordinated with local treating physicians. Conditions treated — complete list Liver cirrhosis — alcoholic, viral (HBV, HCV), autoimmune, metabolic (MASLD/NASH), cryptogenic Acute-on-chronic liver failure (ACLF) — all grades per APASL-AARC criteria Acute liver failure (ALF) — all aetiologies including drug-induced, viral, Wilson’s Hepatitis B — chronic HBV, HBV reactivation, HBV-related cirrhosis and HCC Hepatitis C — DAA therapy, retreatment, post-SVR surveillance Autoimmune hepatitis (AIH) — diagnosis, treatment, overlap syndromes Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) Wilson’s disease and hereditary haemochromatosis MASLD / NAFLD / NASH — metabolic fatty liver disease Drug-induced liver injury (DILI) and herb-induced liver injury (HILI) Hepatocellular carcinoma (HCC) — surveillance, staging, locoregional therapy, transplant assessment Variceal bleeding, ascites, spontaneous bacterial peritonitis (SBP) Hepatic encephalopathy and hepatorenal syndrome (HRS) Portal hypertension and Budd-Chiari syndrome Liver transplant evaluation, LDLT candidacy, post-transplant aftercare Where to see Dr. Chetan Kalal in Mumbai Primary hospital: Gleneagles Hospital Mumbai — Associate

Most patients who come to me have already seen a doctor. Some have seen several. What brings them to a subspecialty hepatologist is usually not the absence of a diagnosis — it’s the absence of a clear path forward. This article explains what a subspecialty hepatology consultation actually involves, how it differs from a general gastroenterology review, and what patients — in Mumbai, across India, and internationally — should expect when they book with me. What is a DM Hepatologist and why does it matter? In India, the highest postgraduate qualification in hepatology is the DM (Doctorate of Medicine) in Hepatology — a three-year subspecialty training program following an MD, focused exclusively on liver and biliary diseases, liver transplantation, and advanced hepatological management. It is distinct from a DM Gastroenterology and from an MD Medicine or MD Gastroenterology. I am the first DM-qualified Hepatologist in Maharashtra — a distinction that reflects both the timing of the qualification pathway’s establishment in India and the depth of subspecialty training it requires. The practical difference for patients: a DM Hepatologist has trained specifically in the full spectrum of liver disease management — from acute liver failure requiring ICU-level interventions to complex autoimmune liver diseases, hepatocellular carcinoma staging, and liver transplant evaluation. This is not generalist gastroenterology with a liver interest. It is a distinct subspecialty. A DM Hepatologist in India holds the Doctorate of Medicine in Hepatology — the country’s highest subspecialty qualification in liver disease — following a dedicated three-year training program beyond an MD degree. Dr. Chetan Kalal is the first DM Hepatologist in Maharashtra, practising at Gleneagles Hospital Mumbai with additional affiliations at Breach Candy, Khar Hinduja, and Saifee Hospitals. What conditions does Dr. Chetan Kalal treat? My practice covers the complete spectrum of adult liver disease: Chronic liver disease and cirrhosis Liver cirrhosis (all causes — alcoholic, viral, autoimmune, metabolic), NAFLD/MAFLD (non-alcoholic/metabolic fatty liver disease), autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Wilson’s disease, hereditary haemochromatosis, alpha-1 antitrypsin deficiency, and drug-induced liver injury (DILI). Viral hepatitis Chronic hepatitis B — including antiviral therapy initiation, monitoring, and management of HBV-associated cirrhosis and HCC. Chronic hepatitis C — direct-acting antiviral (DAA) therapy, retreatment for prior failures, and post-SVR surveillance. Acute and critical liver disease Acute liver failure (ALF), acute-on-chronic liver failure (ACLF — all grades including grade 3), variceal bleeding, spontaneous bacterial peritonitis (SBP), hepatic encephalopathy, hepatorenal syndrome (HRS), and ascites management. Liver cancer Hepatocellular carcinoma (HCC) — surveillance in at-risk patients, BCLC staging, locoregional therapy coordination (TACE, ablation), Milan criteria assessment for transplant, and sorafenib/systemic therapy for advanced disease. Liver transplantation Pre-transplant evaluation, MELD scoring, living donor liver transplant (LDLT) candidacy assessment, donor evaluation coordination, and post-transplant aftercare including immunosuppression management, rejection surveillance, and long-term graft health. Rare and complex hepatological disorders Budd-Chiari syndrome, portal vein thrombosis, cholestatic liver diseases, metabolic liver diseases, and overlap syndromes. IPD (Inpatient) Hepatology — Advanced Acute Care For patients admitted to hospital with acute liver presentations, the involvement of a DM Hepatologist in inpatient (IPD) management is not standard everywhere in India — many acute liver cases are managed by general physicians or gastroenterologists without hepatology subspecialty training. In my IPD practice, the clinical focus is on: ACLF management — grading, organ support, and rapid transplant candidacy assessment where indicated Variceal bleeding — endoscopic management coordination, pharmacological secondary prophylaxis, TIPS assessment SBP and HRS — early identification, aggressive fluid management, terlipressin protocols, renal replacement decisions Hepatic encephalopathy — precipitant identification, lactulose/rifaximin protocols, minimal hepatic encephalopathy assessment Acute liver failure — King’s College Criteria assessment, transplant listing urgency evaluation, intensive monitoring The distinction between a gastroenterologist managing an acute liver patient and a DM Hepatologist leading that care is most visible — and most consequential — in these acute presentations. Expert Second Opinion — What it actually means A second opinion in liver disease is one of the most overused and least meaningfully delivered services in Indian healthcare. Here is what it should deliver: What a genuine subspecialty second opinion includes Independent diagnosis verification — not acceptance of the prior diagnosis, but an independent assessment: does the histopathology actually support the stated diagnosis? Does the imaging pattern match? Are the labs consistent with the proposed aetiology? Treatment gap identification — is the current treatment aligned with current international guidelines (EASL 2024, AASLD guidelines)? Are there evidence-based options not being utilised? Is the immunosuppression dose appropriate? Transplant candidacy assessment, if relevant — for any patient with decompensated cirrhosis or ACLF, the question “should transplant be on the table?” should be explicitly answered, not deferred until crisis point. Written structured output — a clinical direction report: confirmed or revised diagnosis, clear rationale, optimal treatment pathway, and defined next steps. Not a letter of endorsement. Not “continue current management.” A genuine liver disease second opinion involves independent re-evaluation of histopathology, imaging, and laboratory data — not confirmation of the existing diagnosis. Dr. Chetan Kalal’s second opinion service delivers a written clinical direction report: revised or confirmed diagnosis with rationale, treatment pathway, and transplant candidacy assessment where applicable. Available in-person in Mumbai and via virtual consultation for patients in USA, UK, UAE, Singapore, Australia, Canada, New Zealand, and across Asia and the Middle East. Who needs a second opinion? A structured subspecialty second opinion is warranted when: You have been diagnosed with cirrhosis or advanced fibrosis and are unclear about the cause, stage, or prognosis Your liver biopsy result has been interpreted without subspecialty hepatology review You have been told you are “not a liver transplant candidate” — particularly if this was determined without applying current ACLF candidacy criteria or by a non-transplant specialist Your current treatment (for hepatitis B, autoimmune hepatitis, PBC, PSC, or NAFLD) does not appear to be working and no explanation has been offered HCC (liver cancer) has been found and you want independent staging confirmation before committing to a treatment pathway You are an NRI patient whose family member in India has received a complex liver diagnosis and you want

The 2024 EASL liver transplant guidelines are the first full revision since 2016. Dr. Chetan Kalal explains what actually changed for Indian patients: ACLF candidacy, expanded indications, MELD 3.0, and why most global updates miss the point for an LDLT-dominant system.

Expert liver transplant care in India by Dr. Chetan Kalal, Associate Director – Hepatology, Gleneagles Hospital Mumbai. Evaluation, MELD scoring, donor options, costs, and outcomes explained.